Gantenerumab

Last updated

Gantenerumab
Gantenerumab Ab(1-11) 5CSZ.png
Fab fragment of gantenerumab (blue) encircling and binding an Aβ(1–11) fibril (bright green). PDB: 5CSZ ​.
Monoclonal antibody
Type Whole antibody
Source Human
Target Beta-amyloid (Aβ40/42)
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6496H10072N1740O2024S42
Molar mass 146276.71 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals. [1] [2]

Gantenerumab binds to and clears aggregated beta amyloid fibers. [3]

A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy. [4] Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease [5] but after five years of treatment, the drug did little to slow cognitive decline in patients. [6]

A study published in 2025 suggests that Gantenerumab appears to reduce the risk of Alzheimer's-related dementia in people with rare genetic mutations mutations that cause the overproduction of amyloid in the brain. These people are normally destined to develop the disease in their 30s, 40s or 50s. [7]

Gantenerumab has been further developed into trontinemab, which started a Phase III trial in 2025. Trontinemab consists of gantenerumab fused to Roche's proprietary Brainshuttle module to help it cross the blood–brain barrier. [8]

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab" (PDF). American Medical Association.
  2. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization. Archived from the original (PDF) on 2012-02-11.
  3. ↑ Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. (January 2018). "The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset". Expert Opinion on Biological Therapy. 18 (1): 25–35. doi:10.1080/14712598.2018.1389885. PMID   29037101. S2CID   4795458.
  4. ↑ Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. (December 2017). "A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease". Alzheimer's Research & Therapy. 9 (1): 95. doi: 10.1186/s13195-017-0318-y . PMC   5723032 . PMID   29221491.
  5. ↑ Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov
  6. ↑ Kolata G (10 February 2020). "An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'". The New York Times.
  7. ↑ Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, et al. (April 2025). "Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial". The Lancet. Neurology. 24 (4): 316–330. doi: 10.1016/S1474-4422(25)00024-9 . PMID   40120616.
  8. ↑ Taylor E (3 October 2025). "Potential Alzheimer's treatment, trontinemab, hits the news – how does it work and is it available?". Alzheimer's Research UK. Retrieved 9 October 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.